



**ASSTON PHARMACEUTICALS LIMITED  
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

To,  
BSE Limited Listing / Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001

Date: - 09/07/2026

**Ref: Asston Pharmaceuticals Limited (ISIN – INE0SJX01015), BSE Code – 544445.**

**Sub: Notice of 2<sup>nd</sup> Extraordinary General Meeting scheduled of F.Y. 2026-27 to be held on 31<sup>st</sup> July, 2026.**

Dear Sir / Madam,

The Extraordinary General Meeting of the Company will be held on Friday, 31<sup>st</sup> July, 2026, at 12.30 P.M. through 'Vide Conferencing' or 'Other Audio Visual Means'. In compliance with section 108 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the Company has arranged from National Securities Depository Limited (NSDL) an e-voting facility for its members to participate in the business to be transacted at the Extraordinary General Meeting.

Pursuant to provisions of Rule 20 of the Companies (Management and Administration) Rules, 2014, the cut-off date for determining the eligibility to vote by electronic means or in the Extraordinary General Meeting has been fixed as July 24<sup>th</sup>, 2026.

Further, pursuant to provisions of Regulation 30(2) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, read with Para A of Part A of Schedule III of said Regulation, please find attached herewith a copy of Notice of Extraordinary General Meeting of the Company.

This is for the information of the Exchange and Members thereof.

Thanking you.

Yours faithfully,

**For Asston Pharmaceuticals Limited**

**Rishi Upadhaya  
Company Secretary and Compliance Officer  
A74324**

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi  
Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id:

aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: www.asstonpharmaceuticals.com



**NOTICE OF EXTRAORDINARY GENERAL MEETING**

**NOTICE** is hereby given that the 2<sup>nd</sup> **Extraordinary General Meeting (“EGM”)** of FY 2026-27 of the members of **ASSTON PHARMACEUTICALS LIMITED (“the Company”)** will be held on Friday, 31<sup>st</sup> July, 2026, at 12:30 P.M. through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”) to transact the following special business:

**1. TO ISSUE EQUITY SHARES ON PREFERENTIAL BASIS.**

To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution**:

**“RESOLVED THAT** pursuant to provisions of Sections 23(1)(b), 42, 62(1)(c) and other applicable provisions, if any, of the Companies Act, 2013, (including any statutory modification or re-enactment thereof for the time being in force) read with the Companies (Prospectus and Allotment of Securities) Rules, 2014 and the Companies (Share Capital and Debentures) Rules, 2014 (including any statutory modification or re-enactment thereof for the time being in force), Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended (“SEBI (ICDR) Regulations, 2018”), the Securities and Exchange Board of India (Substantial Acquisitions of Shares and Takeovers) Regulations, 2011, as amended (“Takeover Regulations”), the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and the rules, regulations, notifications and circulars issued thereunder and other applicable law including any other rules, regulations, guidelines, notifications, circulars and clarifications issued thereon from time to time by the Government of India, the Securities and Exchange Board of India (“SEBI”), Reserve Bank of India (“RBI”), the Ministry of Corporate Affairs, the stock exchange where the equity shares of the Company are listed (“Stock Exchange”), and or any other competent regulatory authority and in accordance with the uniform listing agreement entered into with the Stock Exchange and in accordance with the enabling provisions of the Memorandum of Association and Articles of Association of the Company and subject to such approvals, consents, permissions and sanctions as may be necessary or required from regulatory or other appropriate authorities, including but not limited to the Stock Exchange and SEBI and subject to such conditions and modifications as may be prescribed, stipulated or imposed by any of them while granting such approval, consents, permissions and sanctions and which terms may be agreed to by the Board of Directors of the Company (hereinafter referred to as the “Board”, which term shall be deemed to include any committee(s) constituted / to be constituted by the Board or committee constituted/ to be constituted of management to exercise its powers including the powers conferred by this Resolution) and subject to such terms, conditions and modifications as the Board may in its discretion impose or agree to, the consent of the members of the Company be and is hereby accorded to create, issue, offer and allot, in one or more tranches, by way of Preferential Allotment, up to **24,10,431 (Twenty-Four Lakh Ten Thousand Four Hundred and Thirty-One) Equity Shares** having a face value of ₹10/- (Rupees Ten Only) each at an issue price of ₹115/- (Rupees One Hundred and Fifteen Only) per equity share, including a premium of ₹105/- (Rupees One Hundred and Five Only) per equity share, aggregating up to ₹27,71,99,565/-

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

(Rupees Twenty-Seven Crore Seventy-One Lakh Ninety-Nine Thousand Five Hundred and Sixty-Five Only) on preferential allotment basis in compliance with Chapter V of SEBI (ICDR) Regulations, 2018 and subsequent amendments thereto & on such terms and conditions and in such manner as the Board may in its absolute discretion deem fit, to the following persons/entities as mentioned below:

Sr. No	Name of Proposed Allottee	No. of Equity Shares proposed to be allotted	Name(s) of the Ultimate Beneficial Owner
1.	Vijay Rathee	13,17,391	Vijay Rathee
2.	Vijaylaxmi Infra Projects Private Limited	7,82,608	Kuldip Singh Rathee, Vijay Rathee, Aman Rathee, Prashant Rathee.
3.	Swapneel Pradeep Rane	21,739	Swapneel Pradeep Rane
4.	Jayaram Chitturi	21,739	Jayaram Chitturi
5.	Vashi Neha Parimal	17,391	Vashi Neha Parimal
6.	Padamavathi Chitturi	21,739	Padamavathi Chitturi
7.	Harshad Santosh Talreja	5,217	Harshad Santosh Talreja
8.	Shreevardhan Nitin Tupe	86,956	Shreevardhan Nitin Tupe
9.	Sumit Shrichand Krishnani	21,739	Sumit Shrichand Krishnani
10.	Yashvardhan Nitin Tupe	21,739	Yashvardhan Nitin Tupe
11.	Riya Kishor Rajani	5,217	Riya Kishor Rajani
12.	Neelam Kohli	21,739	Neelam Kohli
13.	Vijay Bloor	21,739	Vijay Bloor
14.	Kunal Jeswani	21,739	Kunal Jeswani
15.	Jitender N. Kewalramani	21,739	Jitender N. Kewalramani
	<b>Total</b>	<b>24,10,431</b>	

**RESOLVED FURTHER THAT:**

- I. The Relevant Date for pricing the issue of Equity Shares in accordance with Regulation 161 of SEBI (ICDR) Regulations, 2018 (as amended) shall be fixed as **Wednesday, 01<sup>st</sup> July, 2026**, being the date 30 (thirty) days prior to the date of this Extra-Ordinary General Meeting, to consider the proposed preferential issue of Equity Shares.
- II. The Equity Shares as may be offered, issued, and allotted in accordance with the terms of this resolution, shall be in dematerialized form.
- III. The Equity Shares to be allotted shall rank pari passu in all respects with the existing Equity Shares of the Company, including dividend.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



- IV. The Equity Shares shall be issued and allotted by the Company to the Proposed Allottees within a period of 15 days from the date of passing of this special resolution provided that where any approval or permission by any regulatory authority or the Central Government or the Stock Exchanges is pending, the allotment shall be completed within a period of 15 days from the date of such approval or permission, as the case may be in compliance with Regulation 170 of the SEBI (ICDR) Regulations, 2018.

**RESOLVED FURTHER THAT** the Equity Shares to be offered, issued and allotted shall be subject to lock in for such periods as prescribed in Regulation 167 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

**RESOLVED FURTHER THAT** the Equity Shares to be so created, offered, issued and allotted shall be subject to the provisions of the Memorandum and Articles of Association of the Company.

**RESOLVED FURTHER THAT** subject to the SEBI (ICDR) Regulations, 2018 and other applicable laws the Board be and is hereby authorized to decide and approve the other terms and conditions of the issue of the above-mentioned Equity Shares and to vary, modify or alter the terms and conditions and size of the issue, as it may deem expedient, without being required to seek any further consent or approval of the Company in a General Meeting.

**RESOLVED FURTHER THAT** the Board be and is hereby authorized to accept any modifications in the proposal as may be required by the agencies involved in such issues but subject to such conditions as the Reserve Bank of India (RBI) / Securities and Exchange Board of India (SEBI) and/or such other appropriate authority, if any, may impose at the time of their approval as agreed by the Board.

**RESOLVED FURTHER THAT** for the purpose of giving effect to this resolution, the Board be and is hereby authorized on behalf of the Company to take all such actions and do all such deeds, matters and things as it may, in its absolute discretion, deem necessary, desirable or expedient and to settle any question, difficulties or doubts that may arise in this regard including but not limited to the offering, issue and allotment of Equity Shares of the Company as it may in its absolute discretion deem fit and proper.

**RESOLVED FURTHER THAT** any of the Director / KMP be and is hereby severally authorized to do all such act (s), deed(s) and things including signing of all forms, documents, filing with Registrar of Companies, Stock Exchanges, Depositories or any other agency as may be necessary and incidental to give effect to the aforesaid Resolution.

**RESOLVED FURTHER THAT** the Board be and is hereby authorized to delegate all or any of the powers herein conferred to Committee of Directors/ any Director(s)/Company Secretary / any Officer(s) of the Company to give effect to the aforesaid resolution.

**RESOLVED FURTHER THAT** all actions taken by the Board in connection with any matter(s) referred to or contemplated in any of the foregoing resolution be and are hereby approved, ratified and confirmed in all respects."

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

For Asston Pharmaceuticals Limited

\_\_\_\_\_  
Rishi Upadhaya  
Mem. No.: A74324  
Company Secretary & Compliance Officer  
**Date: 02-07-2026**  
**Place: Mumbai**

**Notes:**

1. Statement pursuant to Section 102(1) of the Companies Act, 2013 ('Act'), in respect of the Businesses to be transacted at the Extraordinary General Meeting ('EGM') is annexed hereto.
2. The Ministry of Corporate Affairs ('MCA') has, vide its General Circular No. 03/2025 dated September 22, 2025 in relation to 'Clarification on holding of Annual General Meeting ('AGM') and Extraordinary General Meeting ('EGM') through Video Conferencing ('VC') or Other Audio Visual Means ('OAVM') read with Circular 20/2020 dated May 5, 2020, No. 14/2020 dated April 8, 2020, Circular No. 17/2020 dated April 13, 2020, Circular No. 33/2020 dated September 28, 2020, Circular No. 39/2020 dated December 31, 2020, Circular No. 10/2021 dated June 23, 2021, Circular No. 20/2021 dated December 8, 2021 and Circular No. 2/2022 dated May 5, 2022, Circular No. 10/2022 dated December 28, 2022, Circular No. 09/2023 dated September 25, 2023, Circular No. 09/2024 dated September 19, 2024 issued by the ('MCA') and Circular No. 03/2025 dated September 22, 2025 (hereinafter collectively referred to as 'MCA Circulars') allowed the companies to conduct their Annual General Meetings and Extraordinary General Meeting to be held **till further orders** through VC / OAVM, without the physical presence of the Members at a common venue by following the guidelines specified in the said MCA Circulars. Further, Securities and Exchange Board of India ('SEBI'), vide its circulars dated May 12, 2020, January 15, 2021, May 13, 2022, January 5, 2023 and October 3, 2024 ('SEBI Circulars') and other applicable circulars issued in this regard, have provided relaxations from compliance with certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR').
3. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020, May 05, 2020, May 05, 2022 December 28, 2022, September, 25, 2023, September 19, 2024 and September, 22, 2025, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM/EGM. For this purpose, the Company has made an arrangement with National Securities Depository Limited

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED  
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

(NSDL) for facilitating voting through electronic means, as the authorized e-Voting's agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the EGM will be provided by NSDL.

4. The Members can join the EGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the EGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the EGM without restriction on account of first come first served basis.
5. The attendance of the Members attending the EGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
6. Pursuant to the Circular No. 14/2020 dated 8th April, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the Members is not available for this EGM. However, the Body Corporates are entitled to appoint authorized representatives to attend the EGM through VC/OAVM and participate thereat and cast their votes through e-voting.
7. In compliance with the MCA Circulars and SEBI Circulars, Notice of the EGM is being sent only through permitted mode to Members. Members may note that the Notice will also be available on the Company's website at <https://asstonpharmaceuticals.com/>, websites of the Stock Exchange i.e. BSE Limited at [www.bseindia.com](http://www.bseindia.com). The EGM Notice is also available on the website of NSDL (agency for providing the Remote e- Voting facility) i.e. [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
8. In case of joint holders attending the EGM, only such joint holder who is higher in the order of names will be entitled to vote.
9. A person who is not a member as on the record date should treat this Notice for information purpose only.
10. Members are requested to intimate changes, if any, pertaining to their name, postal address, e-mail address, telephone/mobile numbers, PAN, registering of nomination and power of attorney, Bank Mandate details such as name of the bank and branch details, bank account number, MICR code, IFSC code, etc., to their DP in case the shares are held in electronic form and to the RTA in case the shares are held in physical form.
11. To prevent fraudulent transactions, Members are advised to exercise due diligence and notify the Company of any change in address or demise of any Member as soon as possible. Members are also advised to not leave their demat account(s) dormant for long. Periodic statement of holdings should be obtained from the concerned DP and holdings should be verified from time to time.
12. Members desiring inspection of statutory registers during the EGM may send their request in writing to the Company at [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com).
13. Members who wish to inspect the relevant documents referred to in the Notice can send an e-mail to [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com) up to the date of the EGM.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

14. The voting rights of members shall be in proportion to their shares of the paid-up equity share capital of the Company as on the Cut Off date i.e. **Friday, 24<sup>th</sup> July, 2026**.
15. M/s Pragma & Associates, Company Secretaries, Indore has been appointed by the Board of Directors of the Company as Scrutinizer for scrutinizing the voting process through E- Voting for the EGM in a fair and transparent manner.
16. The Chairman shall, at the EGM, at the end of discussion on the resolutions on which voting is to be held, allow voting, by use of remote e-Voting system for all those Members who are present during the EGM through VC/OAVM but have not cast their votes by availing the remote e-Voting facility. The remote e-Voting shall be available by NSDL for voting 15 minutes after the conclusion of the Meeting.
17. The Scrutinizer shall, after the conclusion of voting at the EGM, first count the votes cast during the EGM and, thereafter, unblock the votes cast through remote e-Voting and shall make, not later than 2 working days from the conclusion of the EGM, a Consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
18. The Results declared, along with the Scrutinizer's Report, shall be placed on the Company's website <https://asstonpharmaceuticals.com/> immediately after the declaration of the result by the Chairman or a person authorized by him. The results shall also be immediately forwarded to the Stock Exchanges where the Company's Equity Shares are listed viz. BSE Limited at [www.bseindia.com](http://www.bseindia.com).
19. Members desirous of obtaining additional information regarding the subject matter of the Resolution can request at [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com), so that the required information can be made available at the meeting, to the extent possible.
20. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of contracts or arrangements in which the Directors are interested under Section 189 of the Companies Act, 2013 and all other documents referred to in the Notice will be available for inspection in electronic mode
21. All documents referred to in the accompanying Notice are open to inspection by the members at the Registered Office of the Company on all working days up to the date of the Extraordinary General Meeting between 11:00 A.M. and 1:00 P.M.
22. The Members will be allowed to pose questions during the course of the Meeting. The queries can also be given in advance at [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com).

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER: -**

The remote e-voting period begins on Tuesday, 28<sup>th</sup> July, 2026, at 09:00 A.M. and ends on Thursday, 30<sup>th</sup> July, 2026, at 05:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e., 24<sup>th</sup> July, 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being 24<sup>th</sup> July, 2026

**How do I vote electronically using NSDL e-Voting system?**

*The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:*

**Step 1: Access to NSDL e-Voting system**

**A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode**

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

**Login method for Individual shareholders holding securities in demat mode is given below:**

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	<ol style="list-style-type: none"><li>1. For OTP based login you can click on <a href="https://eservices.nsd.com/SecureWeb/evoting/evotinglogin.jsp">https://eservices.nsd.com/SecureWeb/evoting/evotinglogin.jsp</a>. You will have to enter your 8-digit, DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li><li>2. Existing <b>IDeAS</b> user can visit the e-Services website of NSDL Viz. <a href="https://eservices.nsd.com">https://eservices.nsd.com</a> either on a Personal Computer or on a mobile. On the e-Services home page click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section, this will prompt you to enter your existing User ID and</li></ol>

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “**Access to e-Voting**” under e-Voting services and you will be able to see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

3. If you are not registered for IDeAS e-Services, option to register is available at <https://eservices.nsdl.com>. Select “**Register Online for IDeAS Portal**” or click at <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp>
4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
5. Shareholders/Members can also download NSDL Mobile App “**NSDL Speede**” facility by scanning the QR code mentioned below for seamless voting experience.

**NSDL Mobile App is available on**



**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



<p>Individual Shareholders holding securities in demat mode with CDSL</p>	<ol style="list-style-type: none"><li>1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on login icon &amp; New System Myeasi Tab and then user your existing my easi username &amp; password.</li><li>2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.</li><li>3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on login &amp; New System Myeasi Tab and then click on registration option.</li><li>4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page. The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</li></ol>
<p>Individual Shareholders (holding securities in demat mode) login through their depository participants</p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p>

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**Important note:** Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

**Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.**

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at toll free no. 1800 22 55 33

**B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.**

**How to Log-in to NSDL e-Voting website?**

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.  
*Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.*
4. Your User ID details are given below:

<b>Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical</b>
---

<b>Your User ID is:</b>
-------------------------

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID  For example, if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID  For example, if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company  For example, if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:

- a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
- b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- c) How to retrieve your 'initial password'?  
If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.  
If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



6. If you are unable to retrieve or have not received the “Initial password” or have forgotten your password:
  - a) Click on “**Forgot User Details/Password?**”(If you are holding shares in your demat account with NSDL or CDSL) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - b) **Physical User Reset Password?**” (If you are holding shares in physical mode) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - c) If you are still unable to get the password by aforesaid two options, you can send a request at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
  - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
8. Now, you will have to click on “Login” button.
9. After you click on the “Login” button, Home page of e-Voting will open.

**Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.**

**How to cast your vote electronically and join General Meeting on NSDL e-Voting system?**

1. After successful login at Step 1, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select “EVEN” of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on “VC/OAVM” link placed under “Join Meeting”.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**1. General guideline for shareholders:**

2. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail info@pragyaandassociates.com with a copy marked to [evoting@nsdl.com](mailto:evoting@nsdl.com). Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
3. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "[Forgot User Details/Password?](#)" or "[Physical User Reset Password?](#)" option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com) to reset the password.
4. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or call on.: 022 - 4886 7000 or send a request to Mr. Rahul Rajbhar at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in)

**Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:**

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com) .
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com) . If you are an Individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A)** i.e. **Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.**
3. Alternatively, shareholder/members may send a request to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM/EGM ARE AS UNDER: -**

1. The procedure for e-Voting on the day of the EGM/AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the AGM/EGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM/EGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the AGM/EGM. However, they will not be eligible to vote at the AGM/EGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM/EGM shall be the same person mentioned for Remote e-voting.

**INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE EGM/AGM THROUGH VC/OAVM ARE AS UNDER:**

1. Member will be provided with a facility to attend the EGM/AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM" placed under "Join meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com) .The same will be replied by the company suitably.
6. Members who have questions or seeking clarifications on the Notice or on the proposals as contained in this Notice are requested to send e-mail to the Company [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com) on or before Thursday, 23<sup>rd</sup> July, 2026. This would enable the company to compile the information and provide the replies at/after the meeting. The Company will allot time for members to express their views or give comments during the meeting. The members who wish to speak at the meeting need to register themselves as a speaker by sending an e-mail from their registered e-mail ID mentioning their

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

name, DP ID and Client ID/Folio number and mobile number, on email ID [compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com) on or before Thursday, 23<sup>rd</sup> July, 2026. Depending on the availability of time, the Company reserves the right to restrict the number of speakers at the meeting. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**EXPLANATORY STATEMENT PURSUANT TO THE PROVISIONS OF SECTION 102 OF THE COMPANIES ACT, 2013:**

**ITEM NO.: 01**

**TO ISSUE EQUITY SHARES ON PREFERENTIAL BASIS.**

The Board of Directors of the Company ("Board") at its meeting held on **July 02<sup>nd</sup>, 2026**, subject to the approval of the members by way of passing a Special Resolution and subject to other necessary approval(s), as may be required, have decided/approved the proposal for raising of fund by issuance up to 24,10,431 (Twenty-Four Lakh Ten Thousand Four Hundred and Thirty-One) Equity Shares having a face value of ₹10/- (Rupees Ten Only) each at an issue price of ₹115/- (Rupees One Hundred and Fifteen Only) per equity share, including a premium of ₹105/- (Rupees One Hundred and Five Only) per equity share, aggregating up to ₹27,71,99,565/- (Rupees Twenty-Seven Crore Seventy-One Lakh Ninety-Nine Thousand Five Hundred and Sixty-Five Only), on cash basis, on preferential allotment basis in accordance with the provisions of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations").

In terms of Section 62(1)(c) read with Sections 42 of the Companies Act, 2013 and rules made thereunder ("Act"), and in accordance with the provisions of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("ICDR Regulations") as amended, and on the terms and conditions and formalities as stipulated in the Act and the ICDR Regulations, the Preferential Issue requires approval of the shareholders of the Company by way of a special resolution.

Accordingly, consent of the members is being sought in terms of Section 42 & 62 of the Companies Act 2013 and Chapter V of the SEBI (ICDR) Regulations, 2018.

The details of the issue and other particulars as required in terms of Chapter V of the SEBI (ICDR) Regulations, 2018, Rule 13 of Companies (Share Capital and Debentures) Rules, 2014, and Rule 14 of Companies (Prospectus and allotment of securities) Rules, 2014 in relation to the above-mentioned Special Resolution are given as under.

**1. List of Allottees for Preferential Allotment of Equity Shares:**

<b>Sr. No</b>	<b>Name of Proposed Allottee(s)</b>	<b>No. of Equity Shares proposed to be allotted</b>	<b>Name of the Ultimate Beneficial Owner</b>
1.	Vijay Rathee	13,17,391	Vijay Rathee
2.	Vijaylaxmi Infra Projects Private Limited	7,82,608	Kuldip Singh Rathee, Vijay Rathee, Aman Rathee, Prashant Rathee.
3.	Swapneel Pradeep Rane	21,739	Swapneel Pradeep Rane
4.	Jayaram Chitturi	21,739	Jayaram Chitturi
5.	Vashi Neha Parimal	17,391	Vashi Neha Parimal

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

6.	Padamavathi Chitturi	21,739	Padamavathi Chitturi
7.	Harshad Santosh Talreja	5,217	Harshad Santosh Talreja
8.	Shreevardhan Nitin Tupe	86,956	Shreevardhan Nitin Tupe
9.	Sumit Shrichand Krishnani	21,739	Sumit Shrichand Krishnani
10.	Yashvardhan Nitin Tupe	21,739	Yashvardhan Nitin Tupe
11.	Riya Kishor Rajani	5,217	Riya Kishor Rajnani
12.	Neelam Kohli	21,739	Neelam R Kohli
13.	Vijay Bloor	21,739	Vijay Bloor
14.	Kunal Jeswani	21,739	Kunal Jeswani
15.	Jitender N. Kewalramani	21,739	Jitender N. Kewalramani

**2. Objects of the Issue:**

The Company shall utilize the proceeds from the preferential issue of the Equity Shares towards following objects:

<b>Purpose</b>	<b>Total estimated amount to be utilized for each of the objects * (Rs. In Cr.)</b>	<b>Tentative Timeline for Utilization</b>	<b>Till Funds are utilized, disclose the mode in which funds will be kept</b>
Funding the incremental working capital requirements of our Company	19.22	Within 1 year from the date of receipt of Funds	Deposited in schedule Commercial Bank.
Repayment and/or prepayment, in part or full, of certain of our outstanding borrowings availed by our Company	2.00	Within 1 year from the date of receipt of Funds	Deposited in schedule Commercial Bank.
Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit	2.00	Within 1 year from the date of receipt of Funds	Deposited in schedule Commercial Bank.
General Corporate Purpose and issue related expenses	4.5	Within 1 year from the date of receipt of Funds	Deposited in schedule Commercial Bank.

**\* Considering 100% subscription of equity shares.**

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



The above stated fund requirements are based on management estimates and have not been appraised by any bank, financial institution or any other external agency. They are based on current circumstances of our business. The Company may have to revise its estimates from time to time on account of various factors beyond its control, such as financial, market and sectoral conditions, competitive environment, business performance and strategy and interest or exchange rate fluctuations. Consequently, the funding requirements of our Company and deployment schedules are subject to revision in the future at the discretion of the management, however, the same will be done in compliance with applicable laws.

**3. Maximum number of specified securities to be issued and price of the securities:**

The resolution set out in the accompanying notice authorizes the Board to issue and allot 24,10,431 (Twenty-Four Lakh Ten Thousand Four Hundred and Thirty-One) Equity Shares having a face value of ₹10/- (Rupees Ten Only) each at an issue price of ₹115/- (Rupees One Hundred and Fifteen Only) per equity share, including a premium of ₹105/- (Rupees One Hundred and Five Only) per equity share, aggregating up to ₹27,71,99,565/- (Rupees Twenty-Seven Crore Seventy-One Lakh Ninety-Nine Thousand Five Hundred and Sixty-Five Only), on cash basis, on preferential allotment basis in accordance with the provisions of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations").

**4. Pricing and / or Basis on which the price has been arrived at and justification for the price (including premium, if any)**

The equity shares of the company are listed on stock exchange (BSE Limited) and are frequently traded in accordance with regulation 164 of the ICDR Regulations. The floor price of Rs. 115/- is determined as per the pricing formula prescribed under the SEBI ICDR Regulations for the preferential issue of equity shares

- 90 Trading Days volume weighted average price (VWAP) of the Equity Shares of the Company quoted on BSE preceding the Relevant Date: Rs. 75.60/- per Share
- 10 Trading Days volume weighted average price (VWAP) of the Equity Shares of the Company quoted on BSE preceding the Relevant Date: Rs. 69.79/- per Share
- **Report of independent registered valuer:** Considering that the allotment shall be more than 5% of the post issue fully diluted share capital of the Company, the price of Rs. 115/- of the Equity Shares to be issued and allotted to the proposed allottees has been determined taking into account the valuation report dated 02<sup>nd</sup> July, 2026 issued by Ms. Amninder Kaur, Registered Valuer (IBBI Registration No. IBBI/RV/03/2021/14025) and ICSI Registered Valuer (ICSI RVO/COP/SFA0620/197), in accordance with Regulation 166A of the ICDR Regulations ("Valuation Report"). The Valuation Report shall be available for inspection by the members and the same may be accessed on the Company's website at the link: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com) under Investor Tab.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: [aston.tech14@gmail.com](mailto:aston.tech14@gmail.com)/[compliance@asstonpharmaceuticals.com](mailto:compliance@asstonpharmaceuticals.com)

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



The Board proposes to issue Equity Shares at a price of Rs. 115/- (Rupees One Hundred Fifteen Only) per Equity Share, which is not less than the floor price determined in accordance with SEBI ICDR Regulations. The Board found it justified considering the current scenario of the Company etc.

**Method of determination of price as per the Articles of Association of the company:**

Not applicable as the Articles of Association of the company is silent on the determination of a floor price / minimum price of the equity shares issued on preferential basis.

The Articles of Association of the issuer do not provide a specific method of determination floor price so the price calculated under the relevant Regulation of the Securities and Exchange Board of India ("Issue of Capital and Disclosure Requirements") Regulations, 2018 shall be considered as the issue price for equity shares to be allotted pursuant to the preferential issue.

**5. Relevant date with reference to which the price has been arrived at:**

The Relevant Date in terms of Regulation 161 of SEBI (ICDR) Regulations, 2018, for determining the price of Equity Shares to be issued with reference to the proposed allotment is Wednesday, 01<sup>st</sup> July 2026.

**6. The class or classes of persons to whom the allotment is proposed to be made:**

The proposed preferential allotment of Equity Shares is proposed to be made to the Non-Promoters category (Public).

**7. Intention of promoters, directors, or key managerial personnel (KMP) or senior management of the issuer to subscribe to the offer:**

Except for Mr. Yashvardhan Nitin Tupe, Non-Executive Director of the Company, no other existing Promoters, Directors, Key Managerial Personnel, or Senior Management of the Company have shown their intention to subscribe to the proposed Preferential Issue of Equity Shares.

**8. The change in control, if any, in the company that would occur consequent to the preferential offer;**

The proposed Preferential Allotment of Equity Shares will not result in any change in the management and control of the Company.

**9. Time frame within which the preferential allotment shall be completed:**

As required under the Regulation 170 of SEBI (ICDR) Regulations 2018, the Company shall complete the allotment of Equity Shares within a period of 15 days from the date of passing of this Special Resolution by the shareholders in General Meeting, provided that where any approval or permission by any regulatory authority or the Stock Exchange is pending, the allotment shall be completed within a period of 15 days from the date of such approval or permission.

**10. Shareholding pattern before and after the Preferential Issue would be as follows:**

Please refer to Annexure A to this notice for details.

**11. Consequential Changes in the Voting Rights:**

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

Voting rights will change according to the change in the shareholding pattern mentioned above.

**12. Identity of the natural persons who are the ultimate beneficial owners of the shares proposed to be allotted and/or who ultimately control the proposed allottees, the percentage of post preferential issues that may be held by them and change in control if any in the issuer consequent to the preferential issues:**

The Equity Shares are proposed to be allotted to persons belonging to Non-Promoters.. No change in control or management of the Company is contemplated consequent to the proposed preferential issue. The pre and post issue holding of the proposed allottees are as under:

Name of the Proposed Allottees	Category	Present pre-issue Shareholding As on 26.06.2026		Post issue shareholding*		Ultimate beneficial owners
		Pre-issue Holding	% of total equity capital	Post-issue Holding	% of total equity capital	
Vijay Rathee	Public	0	0	13,17,391	12.06	Vijay Rathee
Vijaylaxmi Infra Projects Private Limited	Public	0		7,82,608	7.16	Kuldip Singh Rathee, Vijay Rathee, Aman Rathee, Prashant Rathee.
Swapneel Pradeep Rane	Public	0	0	21,739	0.20	Swapneel Pradeep Rane
Jayaram Chitturi	Public	0	0	21,739	0.20	Jayaram Chitturi
Vashi Neha Parimal	Public	0	0	17,391	0.16	Vashi Neha Parimal
Padamavathi Chitturi	Public	0	0	21,739	0.20	Padamavathi Chitturi
Harshad Santosh Talreja	Public	0	0	5,217	0.05	Harshad Santosh Talreja
Shreevardhan Nitin Tupe	Public	15000	0.17	1,01,956	0.93	Shreevardhan Nitin Tupe

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)

Sumit Shrichand Krishnani	Public	0	0	21,739	0.20	Sumit Shrichand Krishnani
Yashvardhan Nitin Tupe	Public	33056	0.38	54,795	0.50	Yashvardhan Nitin Tupe
Riya Kishor Rajani	Public	1000	0.1	6,217	0.06	Riya Kishor Rajnani
Neelam Kohli	Public	0	0	21,739	0.20	Neelam R Kohli
Vijay Bloor	Public	0	0	21,739	0.20	Vijay Bloor
Kunal Jeswani	Public	0	0	21,739	0.20	Kunal Jeswani
Jitender N. Kewalramani	Public	0	0	21,739	0.20	Jitender N. Kewalramani

**13. The Current and Proposed status of the allottees post the preferential issue namely, promoter or non-promoter:**

Sr. No.	Name of the Proposed Allottees	Current status of the allottees namely promoter or non promoter	Proposed status of the allottees post the preferential issue namely promoter or non-promoter
1.	Vijay Rathee	Non-Promoter	Non-Promoter
2.	Vijaylaxmi Infra Projects Private Limited	Non-Promoter	Non-Promoter
3.	Swapneel Pradeep Rane	Non-Promoter	Non-Promoter
4.	Jayaram Chitturi	Non-Promoter	Non-Promoter
5.	Vashi Neha Parimal	Non-Promoter	Non-Promoter
6.	Padamavathi Chitturi	Non-Promoter	Non-Promoter
7.	Harshad Santosh Talreja	Non-Promoter	Non-Promoter
8.	Shreevardhan Nitin Tupe	Non-Promoter	Non-Promoter
9.	Sumit Shrichand Krishnani	Non-Promoter	Non-Promoter
10.	Yashvardhan Nitin Tupe	Non-Promoter	Non-Promoter
11.	Riya Kishor Rajani	Non-Promoter	Non-Promoter
12.	Neelam Kohli	Non-Promoter	Non-Promoter
13.	Vijay Bloor	Non-Promoter	Non-Promoter
14.	Kunal Jeswani	Non-Promoter	Non-Promoter
15.	Jitender N. Kewalramani	Non-Promoter	Non-Promoter

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**14. The number of persons to whom allotment through preferential issue have already been made during the year in terms of number of securities as well as price:**

No preferential allotment has been made to any person during the current Financial year 2026-27.

**15. The justification for the allotment proposed to be made for consideration other than cash together with valuation report of the Registered Valuer:**

Not Applicable as present issue is for cash basis.

**16. Undertakings:**

- I. The Issuer Company undertakes that they shall recompute the price of the specified securities in terms of the provision of SEBI (ICDR) Regulations, 2018, as amended where it is required to do so.
- II. The Issuer Company undertakes that if the amount payable on account of the re-computation of price is not paid within the time stipulated in terms of the provision of SEBI (ICDR) Regulations, 2018, the specified securities shall continue to be locked-in till the time such amount is paid by the allottees.

**17. Disclosure as specified under Regulation 163(1)(i) of SEBI(ICDR) Regulations 2018**

Disclosure is not applicable in the present case as neither the company nor its promoters/ directors are willful defaulters or fraudulent borrower.

**18. Name and the address of Valuer who performed valuation**

The valuation was performed by CS Amninder Kaur, Registered Valuer (IBBI Registration IBBI/RV/03/2021/14025) and ICSI Registered Valuer (ICSI RVO/COP/SFA0620/197) having his office at 69, Phase-3, SKS Nagar, Ludhiana-141013 (Punjab).

**19. Company Secretary's Certificate**

The certificate from M/s. Pragma & Associates, Practicing Company Secretary (ICSI Membership No.: 65240 CP No: 24481) certifying that the preferential issue is being made in accordance with the requirements contained in the SEBI ICDR Regulations shall be made available for inspection by the Members during the meeting and will also be made available on the Company's website and will be accessible at link [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com) under Investor Tab.

**20. Lock-in period**

The aforesaid allotment of Equity Shares on a preferential basis shall be locked in as per Regulation 167 of Chapter V of the SEBI (ICDR) Regulations, 2018, as amended. The entire pre-preferential allotment shareholding of the allottees, if any, shall be locked-in as per Regulation 167 (6) of Chapter V of the SEBI (ICDR) Regulations, 2018.

**21. Material Terms of Issue of Equity Shares**

The Equity Shares allotted pursuant to this issue in terms of this resolution shall rank pari-passu with the existing equity shares of the Company in all respects.

**22. Disclosure pursuant to the provisions of Schedule VI of SEBI (ICDR) Regulations 2018:**

It is hereby declared that neither the Company nor its promoters and directors are willful defaulters or fraudulent borrowers as defined under SEBI (ICDR) Regulations, 2018 and none of its directors

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



or Promoters are fugitive economic offender as defined under SEBI (ICDR) Regulations, 2018 and hence providing disclosures specified in Schedule VI of SEBI (ICDR) Regulations 2018 does not arise.

**23. Particulars of the offer, Kinds of Securities Offered, Price of the Securities Offered, including date of passing of the Board resolution:**

Issue of up to 24,10,431 (Twenty-Four Lakh Ten Thousand Four Hundred and Thirty-One) Equity Shares having a face value of ₹10/- (Rupees Ten Only) each at an issue price of ₹115/- (Rupees One Hundred and Fifteen Only) per equity share, including a premium of ₹105/- (Rupees One Hundred and Five Only) per equity share, aggregating up to ₹27,71,99,565/- (Rupees Twenty-Seven Crore Seventy-One Lakh Ninety-Nine Thousand Five Hundred and Sixty-Five Only) on preferential allotment basis. Date of passing Board Resolution for the aforesaid Preferential Issue is 02<sup>nd</sup> July, 2026.

**24. Amount which the company intends to raise by way of such securities:**

The Company intends to raise a total of Rs. 27,71,99,565/- (Rupees Twenty-Seven Crore Seventy-One Lakh Ninety-Nine Thousand Five Hundred and Sixty-Five Only), through issue of Equity shares.

**25. Contribution being made by the promoters or directors either as part of the offer or separately in furtherance of objects:**

Except Mr. Yashvardhan Nitin Tupe, Non- Executive Director of the Company intent to subscribe to the Equity Share, no other contribution is being made by the existing promoters, including promoter group or directors, either as part of the offer or separately in furtherance of the objects.

**26. Principle terms of assets charged as securities:**

Not Applicable

**27. Monitoring of Utilization of Funds:**

Since the issue size is less than Rs. 100 Crore, the Company is not required to appoint a credit rating agency as a monitoring agency in terms of Regulation 162A of the SEBI ICDR Regulations.

In accordance with the provisions of Sections 42 and 62 of the Act, read with applicable rules thereto and relevant provisions of the SEBI ICDR Regulations, the approval of the members for the issue of equity shares to the Investor(s) is being sought by way of a special resolution as set out in the said item no. 1 of the Notice.

The Board of Directors believes that the proposed preferential issue is in the best interest of the Company and its members and, therefore, recommends the resolution at Item No.1 of the accompanying Notice for approval by the members of the Company as a Special Resolutions.

None of the Directors, Key Managerial Personnel or their relatives thereof are in any way financially or otherwise concerned or interested in the passing of this special resolution as set out at Item No. 1 of this notice except and to the extent of their shareholding in the Company and Equity Share proposed to be subscribe in present Issue.

The documents referred to in the notice/ explanatory statement will be available for inspection by the Members of the Company as per applicable law.

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

**For Asston Pharmaceuticals Limited**

**Rishi Upadhaya**  
**Mem. No.: A74324**  
**Company Secretary & Compliance Officer**  
**Date: 02-07-2026**  
**Place: Mumbai**

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**Annexure - A - Pre and Post Preferential Issue Shareholding Pattern of the Company**

Sr. No.	Category of Shareholder(s)	Pre-Issue (As on 26.06.2026)		Post-Issue	
		No. of Shares held	% of share holding	No. of Shares held	% of share holding
<b>A</b>	<b>Promoters &amp; Promoter Group Holding</b>				
<b>A1</b>	<b>Indian</b>				
	Individuals/Hindu undivided Family	4312480	50.66	4312480	39.48
	Bodies Corporate	0	0	0	0
	Sub Total A1	4312480	50.66	4312480	39.48
<b>A2</b>	<b>Foreign</b>				
	Individuals/Hindu undivided Family	-	-	-	-
	Bodies Corporate	-	-	-	-
	Sub Total A	-	-	-	-
	<b>Total Promoters &amp; Promoter Group Holding A1 + A2</b>	<b>4312480</b>	<b>50.66</b>	<b>4312480</b>	<b>39.48</b>
<b>B</b>	<b>Public shareholders</b>				
<b>B1</b>	<b>Institutions</b>	-	-	-	-
<b>B2</b>	<b>Institutions (Domestic)</b>	-	-	-	-
<b>B3</b>	<b>Institutions (Foreign)</b>	-	-	-	-
<b>B4</b>	<b>Central Government/ State Government(s)/ President of India</b>	-	-	-	-
<b>B5</b>	<b>Non-Institutions</b>				
	Resident Individuals	3618737	42.51	5203082	47.64
	Non Resident Indians (NRIs)	127200	1.50	170678	1.56

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)



**ASSTON PHARMACEUTICALS LIMITED**  
**(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)**

	Bodies Corporate	249650	2.93	1032258	9.45
	HUF	204293	2.40	204293	1.87
	Trust	-	-	-	-
	Firm	-	-	-	-
	<b>Total Public Holding B1+B2+B3+B4+B5</b>	<b>4199880</b>	<b>49.34</b>	<b>6610311</b>	<b>60.52</b>
<b>C</b>	<b>Shares held by custodians</b>	-	-	-	-
	<b>Grand Total A + B + C</b>	<b>8512360</b>	<b>100</b>	<b>10922791</b>	<b>100</b>

**CIN: U24304MH2019PLC324187**

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane,  
Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com

Web: [www.asstonpharmaceuticals.com](http://www.asstonpharmaceuticals.com)